» Articles » PMID: 33238405

Genotype-Phenotype Correlations in Duchenne and Becker Muscular Dystrophy Patients from the Canadian Neuromuscular Disease Registry

Overview
Journal J Pers Med
Date 2020 Nov 26
PMID 33238405
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Duchenne muscular dystrophy (DMD) is a fatal neuromuscular disorder generally caused by out-of-frame mutations in the gene. In contrast, in-frame mutations usually give rise to the milder Becker muscular dystrophy (BMD). However, this reading frame rule does not always hold true. Therefore, an understanding of the relationships between genotype and phenotype is important for informing diagnosis and disease management, as well as the development of genetic therapies. Here, we evaluated genotype-phenotype correlations in DMD and BMD patients enrolled in the Canadian Neuromuscular Disease Registry from 2012 to 2019. Data from 342 DMD and 60 BMD patients with genetic test results were analyzed. The majority of patients had deletions (71%), followed by small mutations (17%) and duplications (10%); 2% had negative results. Two deletion hotspots were identified, exons 3-20 and exons 45-55, harboring 86% of deletions. Exceptions to the reading frame rule were found in 13% of patients with deletions. Surprisingly, C-terminal domain mutations were associated with decreased wheelchair use and increased forced vital capacity. Dp116 and Dp71 mutations were also linked with decreased wheelchair use, while Dp140 mutations significantly predicted cardiomyopathy. Finally, we found that 12.3% and 7% of DMD patients in the registry could be treated with FDA-approved exon 51- and 53-skipping therapies, respectively.

Citing Articles

Integrating Machine Learning-Based Approaches into the Design of ASO Therapies.

Leckie J, Yokota T Genes (Basel). 2025; 16(2).

PMID: 40004514 PMC: 11855077. DOI: 10.3390/genes16020185.


An Updated Analysis of Exon-Skipping Applicability for Duchenne Muscular Dystrophy Using the UMD-DMD Database.

Leckie J, Zia A, Yokota T Genes (Basel). 2024; 15(11).

PMID: 39596689 PMC: 11593839. DOI: 10.3390/genes15111489.


DMD mutations in pediatric patients with phenotypes of Duchenne/Becker muscular dystrophy.

Ge L, Yang Y, Yang Y, Chen Y, Tao N, Zhang L Open Med (Wars). 2024; 19(1):20240916.

PMID: 39588385 PMC: 11587917. DOI: 10.1515/med-2024-0916.


A Novel CRISPR-Cas9 Strategy to Target DYSTROPHIN Mutations Downstream of Exon 44 in Patient-Specific DMD iPSCs.

Dhoke N, Kim H, Azzag K, Crist S, Kiley J, Perlingeiro R Cells. 2024; 13(11).

PMID: 38891104 PMC: 11171783. DOI: 10.3390/cells13110972.


The complex landscape of DMD mutations: moving towards personalized medicine.

Gatto F, Benemei S, Piluso G, Bello L Front Genet. 2024; 15:1360224.

PMID: 38596212 PMC: 11002111. DOI: 10.3389/fgene.2024.1360224.


References
1.
Aartsma-Rus A, Muntoni F . 194th ENMC international workshop. 3rd ENMC workshop on exon skipping: towards clinical application of antisense-mediated exon skipping for Duchenne muscular dystrophy 8-10 December 2012, Naarden, The Netherlands. Neuromuscul Disord. 2013; 23(11):934-44. DOI: 10.1016/j.nmd.2013.06.369. View

2.
Monaco A, Bertelson C, Moser H, Kunkel L . An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics. 1988; 2(1):90-5. DOI: 10.1016/0888-7543(88)90113-9. View

3.
White S, den Dunnen J . Copy number variation in the genome; the human DMD gene as an example. Cytogenet Genome Res. 2006; 115(3-4):240-6. DOI: 10.1159/000095920. View

4.
Roshmi R, Yokota T . Viltolarsen for the treatment of Duchenne muscular dystrophy. Drugs Today (Barc). 2019; 55(10):627-639. DOI: 10.1358/dot.2019.55.10.3045038. View

5.
Nicolas A, Lucchetti-Miganeh C, Ben Yaou R, Kaplan J, Chelly J, Leturcq F . Assessment of the structural and functional impact of in-frame mutations of the DMD gene, using the tools included in the eDystrophin online database. Orphanet J Rare Dis. 2012; 7:45. PMC: 3748829. DOI: 10.1186/1750-1172-7-45. View